S-1/A: Kaya Holdings Files Amendment for Resale of 25 Million Shares Amidst Psychedelic and Cannabis Focus

Kaya Holdings, Inc. files an amendment to its registration statement for the resale of up to 25 million shares of common stock by selling stockholders, as the company focuses on its wellness and mental health operations.

Summary

• Kaya Holdings, Inc. has filed an amendment to its registration statement for the resale of up to 25 million shares of common stock.
• The shares are being offered by selling stockholders and include 280,000 issued shares and 24,720,000 shares issuable upon conversion of convertible promissory notes.
• The company will not receive any proceeds from the sale of these shares.
• Kaya Holdings is focusing on wellness and mental health through operations in psychedelic treatment clinics, medical and recreational cannabis, and CBD products.
• The company operates The Sacred Mushroom Psychedelic Treatment Center in Portland, Oregon, and has experience in the cannabis industry.
• The convertible promissory notes accrue interest at rates ranging from 8% to 10% per annum and are due and payable on December 31, 2026.
• The notes are convertible at a current rate of $0.02 per share, subject to adjustment.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is expanding into a promising market with its psychedelic treatment center, it also faces significant financial challenges, including a history of losses, limited cash, and the need for additional capital. The risks associated with the company's operations and the penny stock status of its shares temper the positive aspects.

Positives

• Kaya Holdings is expanding into the emerging psychedelic treatment market with The Sacred Mushroom facility.
• The company has a decade of experience in the cannabis industry, which may provide operational synergies.
• The company is one of the first recipients of licenses for psilocybin manufacturing and treatment facilities in Oregon.
• The company has a vertically integrated cannabis operation with a range of premium products.
• The company has a presence in both the US and international markets.

Negatives

• The company will not receive any proceeds from the sale of the shares.
• The company has a history of losses and has limited cash on hand.
• The company is dependent on key individuals.
• The company faces significant competition in both the cannabis and psychedelic industries.
• The company's common stock is classified as a penny stock, which may limit trading activity.

Risks

• The company has a history of losses and there is substantial doubt about its ability to continue as a going concern.
• The company has a limited operating history in its current business.
• The company will require additional financing to become commercially viable.
• The company is dependent on key individuals, and the loss of one of these key individuals could have an adverse effect on the company.
• The company must effectively meet the challenges of managing expanding operations.
• Marijuana and psilocybin remain illegal in the United States under federal law.
• The marketing and market acceptance of marijuana and psilocybin may not be as rapid as KAYS expects.
• The company's business activities are part of emerging industries.
• The company's business could be affected by changes in governmental regulation.
• The company will likely face significant competition.
• The company has borrowed and may be required to borrow funds in the future.
• Adverse global economic conditions could have a negative effect on the company's business, results of operations and financial condition and liquidity.
• The company's internal controls may be inadequate, which could cause its financial reporting to be unreliable.
• As a smaller reporting company, the company is subject to scaled disclosure requirements that may make it more challenging for investors to analyze its results of operations and financial prospects.
• The costs of being a public company could result in the company being unable to continue as a going concern.
• The market for the KAYS Shares is extremely limited and sporadic.
• The company's common stock is a penny stock.
• The market for penny stocks has experienced numerous frauds and abuses that could adversely impact KAYSs common stock.
• The price of the company's common stock may become volatile, which could lead to losses by investors and costly securities litigation.
• The board of directors of KAYS has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to common stockholders.
• The ability of the company's principal stockholders, including its CEO, to control its business may limit or eliminate minority stockholders ability to influence corporate affairs.
• The company does not expect to pay cash dividends in the foreseeable future.
• The conversion of the 40 shares of KAYS outstanding Series D Preferred stock by the CEO and an unrelated third-party stockholder would result in the issuance of an additional 27,715,222 shares of KAYS common stock.
• Future sales of shares of KAYS common stock pursuant to Rule 144 under the Securities Act could adversely affect the market price of KAYSs common stock.
• Because the company is not subject to compliance with rules requiring the adoption of certain corporate governance measures, its stockholders have limited protection against interested director transactions, conflicts of interest and similar matters.
• The company may experience dilution of ownership interests because of the future issuance of additional shares of common stock.
• The company has agreed to indemnify its officers and directors against lawsuits to the fullest extent of the law.

Future Outlook

The company plans to utilize The Sacred Mushroom treatment facility as a flagship model to replicate elsewhere in Oregon and in other jurisdictions which may subsequently legalize such psychedelic treatments.

Management Comments

• Management believes that proceeds expected to be received from financing transactions that it is seeking to enter into, combined with existing and anticipated revenues, will alleviate the Companys financial difficulties to a significant extent and will allow the Company to meet its anticipated working capital needs for a period of between twelve and eighteen months from the date of this report.

Industry Context

The announcement comes as the legal cannabis and psychedelic medicine industries are rapidly evolving, with increasing interest in the therapeutic potential of psilocybin and the ongoing debate around federal cannabis legalization.

Comparison to Industry Standards

• The document mentions companies like Compass Pathways, ATAI Life Sciences, and Cybin, which are developing synthetic versions of psilocybin, indicating that Kaya Holdings is operating in a competitive landscape with both pharmaceutical and treatment delivery companies.
• The document notes that the global psychedelic therapeutics market was valued at US$ 3.61 billion in 2021, and estimates the market will reach US$ 8.31 billion by 2028, with a CAGR of 13.2% during the forecast period of 2022-2028, indicating that Kaya Holdings is operating in a high growth market.
• The document also mentions that a recent survey of internet advertised psilocybin treatment prices in Oregon showed that initial prices for one facility range from $300 for a group microdose session and pricing of $900 to $5,000 for an individual high-dose session, with another facility pricing first-time full dose treatments at $15,000, indicating that Kaya Holdings is operating in a high price market.

Legal Proceedings

• From time to time, the company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.

Related Party Transactions

• The Company compensates Craig Frank, its Chief Executive Officer and acting Chief Financial Officer, for his services at the rate of $25,000 per month through a consulting arrangement with Tudog, of which firm Mr. Frank is Chairman and a Principal.
• As of September 30, 2024, the accrued compensation owed to Tudog was approximately $313,636.

Stakeholder Impact

• Shareholders face the risk of dilution and potential losses due to the company's financial situation and the nature of its stock.
• Employees may be affected by the company's financial instability and potential need for cost-cutting measures.
• Customers of The Sacred Mushroom may benefit from the company's expansion into psychedelic treatments.
• Suppliers and creditors may be impacted by the company's financial challenges and ability to meet its obligations.

Next Steps

• The company expects to enroll additional potential candidates in the psilocybin education program.
• The company plans to utilize The Sacred Mushroom treatment facility as a flagship model to replicate elsewhere.
• The company is evaluating redeploying its remaining dispensary license to serve as a delivery hub.

Key Dates

Keywords

Kaya Holdings, psychedelic treatment, cannabis, resale, common stock, convertible notes, The Sacred Mushroom, mental health, OTCQB, penny stock